Miklos D, Riedell P, Bokun A, Chavez J, Schuster S
Target Oncol. 2025; .
PMID: 40035913
DOI: 10.1007/s11523-025-01133-9.
Kater A, Siddiqi T
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):474-481.
PMID: 39644060
PMC: 11665508.
DOI: 10.1182/hematology.2024000570.
Shabani M, Rostamzadeh D, Mansouri M, Jeddi-Tehrani M
Avicenna J Med Biotechnol. 2024; 16(4):201-222.
PMID: 39606680
PMC: 11589431.
DOI: 10.18502/ajmb.v16i4.16737.
Bourdakou M, Melliou E, Magiatis P, Spyrou G
J Transl Med. 2024; 22(1):869.
PMID: 39334178
PMC: 11428436.
DOI: 10.1186/s12967-024-05672-z.
Lopresti L, Tatangelo V, Baldari C, Patrussi L
Front Immunol. 2024; 15:1418527.
PMID: 39281678
PMC: 11392891.
DOI: 10.3389/fimmu.2024.1418527.
T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells.
van Bruggen J, Peters F, Mes M, Rietveld J, Cerretani E, Cretenet G
Blood Adv. 2024; 8(17):4633-4646.
PMID: 39042920
PMC: 11401197.
DOI: 10.1182/bloodadvances.2023011934.
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E
Int J Mol Sci. 2024; 25(12).
PMID: 38928031
PMC: 11203624.
DOI: 10.3390/ijms25126324.
Translation of Data from Animal Models of Cancer to Immunotherapy of Breast Cancer and Chronic Lymphocytic Leukemia.
Gorczynski R
Genes (Basel). 2024; 15(3).
PMID: 38540350
PMC: 10970502.
DOI: 10.3390/genes15030292.
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?.
Vitale C, Griggio V, Perutelli F, Coscia M
Hemasphere. 2023; 7(12):e988.
PMID: 38044959
PMC: 10691795.
DOI: 10.1097/HS9.0000000000000988.
T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.
Lam V, Roleder C, Liu T, Bruss N, Best S, Wang X
Mol Cancer Ther. 2023; 22(9):1040-1051.
PMID: 37420267
PMC: 10525033.
DOI: 10.1158/1535-7163.MCT-22-0762.
Significance of PPARA as a Treatment Target for Chronic Lymphocytic Leukemia.
Xiang X, Li F, Zhou S, Zeng Y, Deng X, Zhang H
PPAR Res. 2023; 2023:8456833.
PMID: 37404899
PMC: 10317583.
DOI: 10.1155/2023/8456833.
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.
Moreno C, Solman I, Tam C, Grigg A, Scarfo L, Kipps T
Blood Adv. 2023; 7(18):5294-5303.
PMID: 37315225
PMC: 10506056.
DOI: 10.1182/bloodadvances.2023010236.
Chronic lymphocytic leukemia presence impairs antigen-specific CD8 T-cell responses through epigenetic reprogramming towards short-lived effectors.
Martens A, Kavazovic I, Krapic M, Pack S, Arens R, Jongejan A
Leukemia. 2023; 37(3):606-616.
PMID: 36658390
PMC: 9851097.
DOI: 10.1038/s41375-023-01817-z.
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?.
Gamal W, Sahakian E, Pinilla-Ibarz J
Blood Adv. 2022; 7(11):2401-2417.
PMID: 36574293
PMC: 10238851.
DOI: 10.1182/bloodadvances.2022008985.
Identification of Six Diagnostic Biomarkers for Chronic Lymphocytic Leukemia Based on Machine Learning Algorithms.
Zhu Y, Gan X, Qin R, Lin Z
J Oncol. 2022; 2022:3652107.
PMID: 36467501
PMC: 9715328.
DOI: 10.1155/2022/3652107.
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).
Cassioli C, Patrussi L, Valitutti S, Baldari C
Int J Mol Sci. 2022; 23(22).
PMID: 36430728
PMC: 9694822.
DOI: 10.3390/ijms232214255.
Mass cytometry analysis reveals attrition of naïve and anergized self-reactive non-malignant B cells in chronic lymphocytic leukemia patients.
Andrieu T, Mondiere P, Jouve P, Dussurgey S, Malassigne V, Servanton H
Front Oncol. 2022; 12:1020740.
PMID: 36387187
PMC: 9661965.
DOI: 10.3389/fonc.2022.1020740.
Molecular Subtyping and Outlier Detection in Human Disease Using the Paraclique Algorithm.
Hagan R, Langston M
Algorithms. 2022; 14(2).
PMID: 36092474
PMC: 9455766.
DOI: 10.3390/a14020063.
Progressive Multifocal Leukoencephalopathy in a Patient with Multifocal Neurological Manifestations Caused by Solitary Brainstem Involvement.
Funatsu A, Nakamichi K, Araki M, Fukumoto T, Mine H
Intern Med. 2022; 62(5):787-792.
PMID: 35945023
PMC: 10036997.
DOI: 10.2169/internalmedicine.9627-22.
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.
Hoferkova E, Kadakova S, Mraz M
Cancers (Basel). 2022; 14(13).
PMID: 35804862
PMC: 9264798.
DOI: 10.3390/cancers14133087.